NephroPlus, Asia’s leading dialysis network, has introduced a pioneering program aimed at addressing the critical issue of Hepatitis C in haemodialysis patients, particularly in regions with limited healthcare resources. This initiative highlights NephroPlus’ ongoing commitment to enhancing patient care and reinforcing the health system’s capabilities.

Hepatitis C is a significant concern among patients undergoing maintenance haemodialysis, often remaining undetected due to its silent progression. The concentrated risk factors within dialysis units necessitate comprehensive prevention, screening, and treatment efforts. In response, NephroPlus has implemented a provider-driven strategy that focuses on improving both patient outcomes and systemic efficiency.

In a pilot study conducted from 2022 to 2024, NephroPlus screened haemodialysis patients across 11 clinics in Bihar and Andhra Pradesh as part of a public-private partnership. The screening process utilized the HCV RNA PCR method, specifically targeting patients under 60 years of age, without comorbidities, and consistently attending at least two dialysis sessions per week over three months. Those diagnosed with Hepatitis C were treated with a 12-week regimen of Sofosbuvir and Velpatisivir, followed by assessments to evaluate viral remission.

The study found Hepatitis C prevalence rates ranging from 2% to 21% across the clinics, with 114 patients testing positive using the HCV IgM ELISA method. Out of these, 94 patients met the study’s inclusion criteria, and 85 consented to participate. The average age of participants was 45 years, with a male-to-female ratio of 80:20. All patients used arteriovenous fistula access, averaging 2.5 dialysis sessions per week.

Of the 85 participants, 37 were found to be HCV RNA PCR negative, underscoring the importance of this method for accurate diagnosis. Among the 48 patients who tested positive, 38 completed the treatment, with 33 achieving viral remission.

Also Read: Oxymed P2: Portable Oxygen Concentrator for Enhanced Mobility and Health

This initiative represents a significant win for all involved. Patients received treatment at no out-of-pocket cost, improving their prognosis and potentially increasing survival rates. The government benefits from reduced long-term healthcare costs, while NephroPlus gains by reducing the overall cost of care, given that treating Hepatitis C is more expensive than managing patients without the infection.

Dr. Suresh Sankar, Senior Vice President of Clinical Affairs at NephroPlus, remarked, “This program by NephroPlus underscores the importance of proactive HCV RNA testing and treatment, which not only addresses the issue of false positives but also significantly reduces the disease burden and infection risk within dialysis units. This initiative has proven to enhance patient outcomes while providing cost-effective solutions for the healthcare system. NephroPlus continues to lead the way in delivering high-quality care and innovative health solutions, setting new standards in the dialysis industry, especially in low-resource environments.”

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.